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Acute myelogenous leukemia (AML), the most common adult acute leukemia, is characterized by the clonal expansion of myeloblasts initiatl
ing from rare leukemic stem cells.1 An estimated 31 490 
new cases of AML and 45 090 deaths due to this disl
ease occurred in 2008 in the US.2 Despite recent adl
vances in the AML therapy, induction failure happened 
in more than 40% of patients and recurrences occurred 
in 50% to 70% even after complete remission. Among 
patients who had complete remission only 20% to 30% 
have longlterm diseaselfree survival.3,4 
The higher recurrence rates after chemotherapy 
are caused by the persistence of leukemia cells with 
high growth potential.5 When this happen there is no 
golden standard treatment for relapsed AML patients.6 
Dendritic cells (DC) are increasingly being used for 
antilcancer therapy.7l10 Many prelclinical studies have 
been performed to establish a strategy for the manul
facture of a DC vaccine for AML immunotherapy.11,12 
Advances in culture techniques and AMLlDC characl
terization have justified clinical application. We present 
a case of AML disease stabilization following therapy 
with dendriticltumor cell hybrid vaccine.
CASe 
A 56lyearlold white female was diagnosed with AML 
subtype M2 (WHO) in 2004. She was initially treated 
with daunorubicin plus cytosine arabinoside (3+7) 
regimen followed by highldose cytarabine. No further 
therapy was given. She went into complete remission 
but relapsed one year later. Immunophenotypic analyl
ses revealed CD33+ in 80% of blasts. The patient was 
given gemtuzumab ozogamicin 9 mg/m2 (day 1 and 14) 
followed by high dose cytarabine. She remained well 
until January of 2007 when she relapsed. We harvested 
100 mL of the patient’s bone marrow containing 60% 
blasts to use in preparing a hybrid dendriticltumor cell 
vaccine in a manner previously described.10 Vaccine was 
applied intradermally in the arm every 4 weeks from 
January 2007 to August 2007. No side effects were seen 
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at the vaccination site or systemically. She had stable disl
ease (roughly 16% blasts) for 9 months under vaccine 
treatment until the disease progressed and she expired. 
DISCUSSIOn
Our patient relapsed even after receiving firstl and secl
ondlline therapy for AML. As there is no golden stanl
dard treatment for relapsed AML6 we decided to use a 
DClbased vaccine. This therapy has the advantage of 
no adverse effects, thus providing a high quality of life 
to patients, in contrast to the usual chemotherapy that 
is associated with serious side effects, which can even 
lead to death. Immunotherapeutic approaches, such 
as therapeutic vaccines, are being used to try to coml
bat this disease. Phase I/II clinical trials showed that 
AMLlderived peptides were safe, and specific immune 
responses were detected.13l16 DClbased vaccination was 
also shown to be feasible in AML patients, but only a 
few clinical trials have been performed, mostly using 
leukemialderived DCs.17l19 In addition, a phase I/II 
trial using WT1 mRNAlelectroporated DCs are being 
performed by Van de Velde et al.20
An advantage of the DCltumor hybrid vaccine is 
that it induces a potent antileukemia response withl
out the need to identify the HLA haplotype of the 
patient, which is necessary for other approaches such 
as the pulsing of DCs with specific peptides or antil
gens.21 Moreover, allogeneic monocytelderived DCs 
showed higher expressions of several molecules (HLAl
DR, CD80, CD83 or CD86), higher production of 
ILl12 and a higher capacity to stimulate allogeneic T 
cells compared to both leukemic DCs and autologous 
monocytelderived DCs.11
Our case report illustrates an effective response to 
allogeneic DClautologous tumor cell vaccine with disl
ease control for 9 months followed by disease progresl
sion. Considering the stabilization of the disease, even 
for a short period, we see this as a promising result, in 
view of the aggressive behavior of AML. The main chall
lenge in treating AML is not in inducing remission after 
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diagnosis, but in preventing relapse.22 It is desirable to 
use DC therapy to eliminate the residual tumor cells 
on the first remission after standard chemotherapeutic 
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treatment.23 Then, vaccination in early stage disease has 
the potential to promote more significant clinical benl
efits in AML patients by preventing relapse.
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